EGFR and non-small cell lung carcinoma: A Phase 3 clinical trial demonstrated superior efficacy of dacomitinib as the first-line treatment for patients with EGFR mutation-positive NSCLC: the median PFS was 14.7 months in the dacomitinib group and 9.2 months in the gefitinib group, suggesting a better therapeutic efficacy as a second-generation EGFR-TKI (24).